The Litigator

THE LITIGATOR

Commentary on Law Affecting Business

The Litigator
AGM :: Affleck Greene McMurtry LLP

THE LITIGATOR

Affleck Greene McMurtry LLP
365 Bay Street, Suite 200  ·  Toronto, Canada
416 360 2800  ·  info@agmlawyers.com  ·  www.thelitigator.ca

Competition Bureau Prescribes Remedy for Pfizer-Hospira Deal

iStock_000015181498_Full

A spoonful of divestiture helps the go down.

Following concerns that Pfizer Inc.’s proposed of Hospira Inc. will result in a substantial , Pfizer has reached an agreement with the Competition Bureau to sell the Canadian assets related to four pharmaceutical products distributed by the pharma giant in Canada.

The Bureau was largely concerned with the supply of the following products in the Canadian pharmaceuticals market:

  • methotrexate sodium tablets,
  • injectable cytarabine,
  • injectable epirubicin hydrochloride, and
  • injectable voriconazole.

Approval of the sale of these four products is in the sole discretion of the Commissioner of Competition, provided that the buyer(s) facilitate effective competition in Canada.

Pfizer announced plans to acquire Hospira in February 2015.

Update: On March 3, 2016, the Bureau announced that it has approved Pfizer Inc.’s sale of four pharma products to Pharmascience in furtherance of the Hospira acquisition.

 

 

Daphne Hooper
Affleck Greene McMurtry LLP

Daphne Hooper

Daphne represents clients in a broad range of commercial matters and is a valued member of the firm’s competition law practice group. Her experience includes complex contractual disputes, multi-jurisdictional class actions, employment matters and professional negligence, including errors and omissions by brokers/dealers and lawyers.

Contributor's Archive

Contributor's Profile